Reported 3 months ago
U.S. health regulators have approved a groundbreaking blood test, the Shield test by Guardant, for colon cancer screening in adults aged 45 and older with average risk. This noninvasive test aims to identify DNA fragments from tumor cells and has demonstrated an 83% cancer detection rate. While it does not replace colonoscopies, the approval may enhance insurance coverage and accessibility for patients who hesitate to undergo traditional screenings.
Source: YAHOO